OBJECTIVE: To determine the cost-utility of selective serotonin reuptake inhibitors (SSRIs) for treating depressive disorders prescribed in primary care (PC). METHOD: A total of 301 participants beginning antidepressant treatment with an SSRI were enrolled in a prospective 6-month follow-up naturalistic study. Incremental cost-utility ratios (ICUR) were obtained for several comparisons among different SSRIs. To address uncertainty in the ICUR's sampling distribution, non-parametric bootstrapping was carried out. RESULTS: Taking into account adjusted total costs and incremental quality of life gained, fluoxetine dominated paroxetine and citalopram with 63.4% and 79.3% of the bootstrap replications in the dominance quadrant, respectively. Additionally, fluoxetine was cost-effective over sertraline with 83.4% of the bootstrap replications below the threshold of 33,936 US$/quality-adjusted life year (30,000 euro/QALY). CONCLUSION: Fluoxetine seems to be a better cost-utility SSRI option for treating depressive disorders in PC.
OBJECTIVE: To determine the cost-utility of selective serotonin reuptake inhibitors (SSRIs) for treating depressive disorders prescribed in primary care (PC). METHOD: A total of 301 participants beginning antidepressant treatment with an SSRI were enrolled in a prospective 6-month follow-up naturalistic study. Incremental cost-utility ratios (ICUR) were obtained for several comparisons among different SSRIs. To address uncertainty in the ICUR's sampling distribution, non-parametric bootstrapping was carried out. RESULTS: Taking into account adjusted total costs and incremental quality of life gained, fluoxetine dominated paroxetine and citalopram with 63.4% and 79.3% of the bootstrap replications in the dominance quadrant, respectively. Additionally, fluoxetine was cost-effective over sertraline with 83.4% of the bootstrap replications below the threshold of 33,936 US$/quality-adjusted life year (30,000 euro/QALY). CONCLUSION:Fluoxetine seems to be a better cost-utility SSRI option for treating depressive disorders in PC.
Authors: Maria Rubio-Valera; María Teresa Peñarrubia-María; Maria Iglesias-González; Martin Knapp; Paul McCrone; Marta Roig; Ramón Sabes-Figuera; Juan V Luciano; Juan M Mendive; Ana Gabriela Murrugara-Centurión; Jordi Alonso; Antoni Serrano-Blanco Journal: Eur J Health Econ Date: 2019-02-06
Authors: Maria Rubio-Valera; Imma Beneitez; María Teresa Peñarrubia-María; Juan V Luciano; Juan M Mendive; Paul McCrone; Martin Knapp; Ramon Sabés-Figuera; Katarzyna Kocyan; Javier García-Campayo; Antoni Serrano-Blanco Journal: BMC Psychiatry Date: 2015-03-31 Impact factor: 3.630